Heart
A planned quantitative troponin I test designed for serial measurement at the point of care, supported by OncoFirm’s own recombinant cTnI calibrator material.
Target
Cardiac troponin I (cTnI)
Sample
Whole blood or plasma
Readout
Quantitative (planned)
Status
Planned
Why it matters
Troponin is the central blood test for diagnosing heart attack, and today’s care pathways rely on precise values measured more than once over a few hours. The long-term goal is point-of-care performance that moves toward laboratory high-sensitivity assays; the first milestone is a reliable quantitative result on the handheld reader.
How OncoFirm will measure it
The same reader, strip design and calibration at each draw are intended to make changes between measurements meaningful.
Every strip carries a fluorescent reference line of known brightness. Reading the test line against it corrects for reader and temperature drift, and the reader flags runs that did not flow correctly.
Each result is stored with the date, operator and lot, ready to share with a clinic record or laboratory system instead of being retyped by hand.
Where it's headed
01
Antibody pairs, fluorescent conjugates and strip layout are selected and tested against the target.
02
Strip, reagents and reader settings are optimized, and pilot lots are built.
03
Precision, linearity, interference and lot-to-lot consistency are measured against reference methods.
04
Performance is evaluated with clinical samples. First release is planned for research use only, followed by regulatory submissions.
Development status. This assay and the OncoFirm platform are in development. They have not been cleared or approved by the FDA and are not available for sale. First products are planned for research use only. Descriptions reflect design goals, not demonstrated performance.
We welcome research, clinical, manufacturing and distribution partners. Tell us how this assay fits your work.